SARS-CoV-2 specific immunity in patients with congenital immune deficiencies

Completed

• Conditions: COVID-19 immunity; immune response against SARS-CoV-2; 10021460; 10047438

• Registration Number: NL-OMON50905
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

- 18 years or older
- congenital immune disorder for with they are monitored at the Infectious
Diseases outpatient clinic of the LUMC
- PCR-confirmed COVID-19 in the past or present

Exclusion Criteria

- received a covid-19 vaccination before start of the study, regardless of the
type of vaccine or vaccine manufacturer

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. SARS-CoV-2 specific T-cell immunity<br /><br>2. SARS-CoV-2 neutralizing antibodies<br /><br>3. SARS-CoV-2 response after vaccination</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>None</p><br>